Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y.
Yamamoto C, et al. Among authors: nakano h.
Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220.
Blood. 2022.
PMID: 35580269
Free PMC article.